Zydus Lifesciences announced the launch of Anyra�, India`s first indigenously developed biosimilar of Aflibercept 2 mg. Zydus has also signed an agreement with Regeneron Pharmaceuticals, Inc. and Bayer. Anyra� is indicated for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), visual impairment due to Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and visual impairment due to Myopic Choroidal Neovascularization (mCNV). With this launch, Zydus reinforces its commitment to advancing ophthalmic care and expanding access to high-quality, affordable biologics for patients across India.Speaking on the launch, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences, said, �At Zydus, we are committed to making advanced biologics accessible to patients who need them most. ANYRA� is a transformative step for affordable retinal care in India. By delivering a high-quality, indigenously developed Aflibercept 2 mg, we are expanding patient access to critical therapies with advanced biologics. Our focus remains on enabling patient-centric outcomes by leveraging science, health and innovation.�Powered by Capital Market - Live News

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Bosentan tablets, oral suspension, 32 mg (USRLD: Tracleer� Tablets for Oral Suspension, 32 mg). Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension (PAH), specifically to improve exercise ability and reduce clinical worsening in children (aged 3 years and older) with idiopathic or congenital PAH. It is a dual endothelin receptor antagonist that lowers high blood pressure in the lungs, typically administered based on body weight. Bosentan 32 mg tablets will be manufactured at the group`s formulation manufacturing facility at SEZ, Ahmedabad. Bosentan 32 mg tablets had annual sales of USD 9.3 mn in the United States (IQVIA MAT December 2025). Powered by Capital Market - Live News

Zydus Lifesciences launched PEPAIR�, India`s first affordable Oscillating Positive Expiratory Pressure (OPEP) device featuring a 3-resistance system designed to help clear congestion and support effective mucous clearance and improve breathing in patients with COPD, Asthma, and Bronchiectasis. PEPAIR� is an innovative, drug-free, handheld device with patented design. More than 90 lakh patients suffer from these chronic respiratory conditions in India. Chronic mucous hypersecretion is a common problem amongst these patients that requires an airway clearance solution for everyday care. PEPAIR� is being launched in agreement with AeroDel Technology Innovations, an Indian medical device company focused on simplifying inhalation through drug-delivery, pulmonary rehabilitation. In a patient-centric approach, Zydus offers PEPAIR™�at an affordable cost of Rs. 990 per unit.Speaking on the launch, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, said, �At Zydus, patient-centric innovation is about advancing healthcare in ways that make everyday care more accessible for patients. With PEPAIR�, India`s first affordable OPEP device, we are introducing a drug free, handheld solution designed to support better breathing for patients with COPD, asthma and bronchiectasis. We look forward to expanding our efforts in advancing respiratory health through this launch�Powered by Capital Market - Live News

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12% (USRLD: Lac-Hydrin Cream�, 12%). Ammonium lactate cream, 12% is a topical prescription medication indicated for the treatment of dry, scaly skin (xerosis) and an inherited dry skin condition called ichthyosis vulgaris. It is used to moisturise the skin by increasing hydration and, as an alpha-hydroxy acid, helps relieve itching, soften skin, and decrease skin scaling. Ammonium lactate cream will be manufactured at the group`s topical manufacturing site at Changodar, Ahmedabad, and distributed by Viona Pharmaceuticals Inc. Ammonium lactate cream had annual sales of USD 15 mn in the United States (IQVIA MAT December 2025). The group now has 430 approvals and has so far filed 505* ANDAs since the commencement of the filing process in FY 2003-04. Powered by Capital Market - Live News

Zydus Lifesciences announced that the company and Zydus Pharmaceuticals USA, Inc., USA, a wholly owned subsidiary, (together referred to as Zydus), have entered into a Settlement Agreement with Astellas in relation to Astellas` Myrbetriq� (generic name: Mirabegron). Under the terms of the Settlement Agreement: 1. Zydus shall pay Astellas an aggregate amount of USD 120 million. 2. Zydus shall additionally pay a prepaid per unit licensing fee on units of Zydus` generic Mirabegron sold in the US from the date of Settlement Agreement till September 2027.This Settlement Agreement concludes all litigations between Astellas and the two companies relating to Myrbetriq� and Mirabegron and enables Zydus to continue marketing its generic Mirabegron in the US. Powered by Capital Market - Live News